Intellia Announces Q4 and Full-Year 2019 Financial Results

- February 27th, 2020

Intellia Therapeutics reported operational highlights and financial results for the fourth quarter and year ended December 31, 2019.

Intellia Therapeutics (NASDAQ:NTLA) reported operational highlights and financial results for the fourth quarter and year ended December 31, 2019.

As quoted in the press release:

“In 2019, we advanced our full-spectrum strategy, guiding both our in vivo and ex vivo lead programs toward the clinic. We also continued to build on our genome editing and delivery capabilities to enable a rapid succession of candidates,” said Intellia President and Chief Executive Officer, John Leonard, M.D. “We are off to a productive start in 2020. We announced the nomination of NTLA-5001, a WT1-directed TCR-T cell therapy for the treatment of AML, and plan to select our third development candidate in the first half of this year, which will be for the treatment of HAE. In addition, in the second half of the year, we expect to begin dosing ATTR patients with NTLA-2001, a potential single-course treatment for ATTR patients. This is anticipated to be the first-ever systemically delivered CRISPR/Cas9-based therapy to enter the clinic, representing an important milestone in our mission to deliver potentially curative therapies from our proprietary modular platform.”

Click here to read the full press release.

Should you invest in the 2020 pharmaceutical market?

Read our FREE outlook report!
 

Leave a Reply